Neumora Therapeutics

Neumora Therapeutics

Neumora was formed in 2020 as an atypical biotech platform, incubated in stealth by Arch Venture Partners and seeded with a $400 million Series A and a $100 million R&D alliance from Amgen (per company filings, 2021). The founding thesis, architected by Chairman and CEO Paul Berns and President Henry Gosebruch, was that precision neuroscience — applying data-driven patient stratification and biomarker-led design to neuropsychiatry and neurodegeneration — could reverse decades of industry failure in brain diseases. The company entered 2021 with rights to eight clinical and preclinical programs, primarily sourced from Amgen's de-prioritized neuroscience portfolio, alongside a proprietary data-science platform called the Neumora Neurocircuitry Atlas. The company's strategy centers on acquiring or licensing de-risked assets that have cleared early safety hurdles, then advancing them through clinical proof-of-concept trials with the goal of reaching registration. Its lead pipeline programs include navacaprant, a kappa opioid receptor antagonist in Phase 3 for major depressive disorder, and NMRA-511 for agitation in Alzheimer's disease. Neumora coordinates multi-site clinical trials across North America and Europe. The company also pursues earlier-stage work in schizophrenia, anhedonia, and ALS, leaning on its computational platform to match patients to mechanisms. In nearly all cases, the original compounds came from an Amgen partnership — an arrangement that gives Neumora a commercial-like pipeline breadth without in-house discovery overhead. Since its founding, Neumora has recruited a management team built from legacy neuroscience- and data-driven drug developers, including former executives from Biogen, AbbVie, and Johnson & Johnson. It operates out of a single headquarters in Watertown, Massachusetts, squarely in the Boston-Cambridge biotech cluster. In September 2023, the firm raised $250 million in an upsized IPO on the Nasdaq under the symbol NMRA (per SEC filing, September 2023), bringing in public-market capital to extend its clinical runway for navacaprant's pivotal Phase 3 readout. No adjacent family-office vehicles, philanthropic arms, or club-investor structures are disclosed. Neumora's structural differentiator is its hybrid parentage: it functions as an independent public company with its own R&D and executive autonomy, but its pipeline was effectively pre-loaded with Amgen's cast-offs under a collaboration that gave Amgen an equity stake and downstream milestones. This allows the firm to behave like a biotech startup — targeting binary regulatory outcomes — while carrying the diversified asset base of a larger pharma subsidiary. The result is a single-purpose neuroscience company that avoids discovery-stage risk entirely, concentrating its capital and human resources on late-stage clinical execution. Succession risk and governance are tied squarely to Berns and the Arch Venture Partners origination network.